BRIEF-NRX Pharma Files Initial Section Of U.S. New Drug Application To The FDA For NRX-100

Reuters
30 Dec 2024
BRIEF-NRX Pharma Files Initial Section Of U.S. New Drug Application To The FDA For NRX-100

Dec 30 (Reuters) - NRX Pharmaceuticals Inc NRXP.O:

  • NRX PHARMACEUTICALS, INC. $(NRXP)$ FILES INITIAL SECTION OF U.S. NEW DRUG APPLICATION TO THE FDA FOR NRX-100 (IV KETAMINE) FOR THE TREATMENT OF SUICIDAL DEPRESSION

  • NRX PHARMACEUTICALS INC - COMPLETION OF NDA FILING EXPECTED IN Q1 2025

Source text: ID:nPn5zkNhra

Further company coverage: NRXP.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10